Immunic announced first patients enrolled in investigator-sponsored phase 2 clinical trial of IMU-838 in combination with Oseltamivir for treatment of patients with COVID-19
| |

Immunic announced first patients enrolled in investigator-sponsored phase 2 clinical trial of IMU-838 in combination with Oseltamivir for treatment of patients with COVID-19

On Jul. 27, 2020, Immunic announced enrollment of the first patients in an investigator-sponsored phase 2 clinical trial…

Akebia announced initiation of investigator-sponsored study evaluating vadadustat for prevention and treatment of ARDS in patients with COVID-19
| | |

Akebia announced initiation of investigator-sponsored study evaluating vadadustat for prevention and treatment of ARDS in patients with COVID-19

On Jul. 14, 2020, Akebia Therapeutics announced the initiation of an investigator-sponsored study evaluating the use of vadadustat,…

Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers formed collaboration to develop Emergent’s COVID-19 hyperimmune globulin product
| | |

Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers formed collaboration to develop Emergent’s COVID-19 hyperimmune globulin product

On Jul. 8, 2020, the Mount Sinai Health System, Emergent BioSolutions and ImmunoTek Bio Centers announced a collaboration…